Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Hybio Pharmaceutical Licenses Semaglutide to Vitamedic for Brazil Market

Fineline Cube Jan 11, 2026
Company Deals

Merck in Talks to Acquire Revolution Medicines for $28‑32 Billion in Oncology Push

Fineline Cube Jan 11, 2026
Company Deals

Takeda Licenses Halozyme’s ENHANZE Technology for Vedolizumab in Global Deal

Fineline Cube Jan 11, 2026
Company Deals

Eisai China and Xuanwu Hospital Forge Strategic Cooperation for Drug R&D

Fineline Cube Jan 11, 2026
Company Deals

InduPro Partners with Lilly on $950M Oncology Deal Using Proximity-Guided Platform

Fineline Cube Jan 10, 2026
Policy / Regulatory

NMPA Issues New Rules to Strengthen Pharmaceutical Contract Manufacturing Oversight

Fineline Cube Jan 9, 2026
Company Drug

Genrix Bio’s GR1803 NDA Accepted for BCMA-Targeted Multiple Myeloma Therapy

Fineline Cube Jan 11, 2026
Company Drug

RemeGen’s RC48 Wins Fourth Breakthrough Therapy Designation for Gastric Cancer Combo

Fineline Cube Jan 11, 2026
Company Deals

OrbusNeich Medical Group to Acquire Majority Stake in Indonesian Distributor PT Revass Utama Medika

Fineline Cube Nov 27, 2023

OrbusNeich Medical Group Ltd (HKG: 6929), a Wholly Owned Foreign Enterprise (WOFE) specializing in vascular...

Company Drug

Kintor Pharmaceutical’s KX-826 Shows Promising Results in Phase III AGA Clinical Trial

Fineline Cube Nov 27, 2023

Kintor Pharmaceutical Ltd (HKG: 9939), a China-based pharmaceutical company, has released topline data from a...

Company Drug

EirGenix’s Trastuzumab Biosimilar Receives European Commission Marketing Approval

Fineline Cube Nov 27, 2023

EirGenix Inc., (6589.TT) a Taiwan-based pharmaceutical company, has announced that it has received marketing approval...

Company Deals

Broncus Medical and Hangzhou Norchant Terminate Licensing Agreement with Cancellation Fee

Fineline Cube Nov 27, 2023

Broncus Medical Inc., (HKG: 2216) a provider of lung disease precision intervention solutions with operations...

Company

FDA Raises Concerns Over Research Conditions at Roche’s Genentech Trial Site

Fineline Cube Nov 27, 2023

The US Food and Drug Administration (FDA) has voiced concerns regarding the research conditions at...

Company Drug

Jiangxi Jemincare Group Secures NMPA Approval for Generic Ibrance Capsules

Fineline Cube Nov 27, 2023

Jiangxi Jemincare Group, a Chinese pharmaceutical company, has announced that it has received market approval...

Policy / Regulatory R&D

China’s CDE Releases Draft Guidelines for Decentralized Trials in Rare Disease Drug Development

Fineline Cube Nov 27, 2023

China’s Center for Drug Evaluation (CDE) has released draft “Technical Guidelines for the Application of...

Company Legal / IP

AbbVie Sues to Protect Rinvoq from Generic Competition in the US Market

Fineline Cube Nov 27, 2023

AbbVie (NYSE: ABBV) has initiated legal action in the US to safeguard its blockbuster drug...

Company Drug

Novo Nordisk Sets February 2024 Launch for Wegovy in Japan, Expanding into Asia

Fineline Cube Nov 27, 2023

Novo Nordisk (CPH: NOVO-B), headquartered in Denmark, has announced that it will launch its anti-obesity...

Company Drug

Jiangsu Hengrui Pharmaceuticals Receives NMPA Approval for Phase Ib/II Study of Dalpiciclib and HRS-8080

Fineline Cube Nov 24, 2023

China-based Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276) has announced that it received approval from...

Company Drug

Fosun Pharmaceutical Gets FDA Green Light for HLX42 ADC Clinical Study

Fineline Cube Nov 24, 2023

Fosun Pharmaceutical (Group) Co., Ltd (HKG: 2196; SHA: 600196) has received approval from the US...

Company Deals

Simcere Pharmaceutical Secures Rights to Develop Rademikibart in China

Fineline Cube Nov 24, 2023

China’s Simcere Pharmaceutical Co., Ltd (HKG: 2096) has entered into an agreement to acquire the...

Company

Bayer Invests USD 130 Million in Parenteral Drugs Manufacturing Site in Germany

Fineline Cube Nov 24, 2023

Bayer (ETR: BAYN) has inaugurated a new state-of-the-art parenteral drugs manufacturing site at its German...

Company

Novo Nordisk Invests DKK 16 Billion to Expand French Production Facility

Fineline Cube Nov 24, 2023

Denmark-based pharmaceutical giant Novo Nordisk (CPH: NOVO-B) has initiated an expansion of its production facility...

Company Deals

Shanghai Escugen Partners with Foreseen Biotechnology for ADC Development

Fineline Cube Nov 24, 2023

China-based Shanghai Escugen has entered into a partnership with domestic firm Foreseen Biotechnology to develop...

Policy / Regulatory

European Commission Proposes Overhaul of Pharmaceutical Legislation

Fineline Cube Nov 24, 2023

The European Commission (EC) is advancing an update to Europe’s 20-year-old pharmaceutical legislation, with the...

Company Drug

Pyrotech Biotechnology’s PTT-936 Gets US FDA Clinical Trial Approval

Fineline Cube Nov 24, 2023

Pyrotech (Beijing) Biotechnology Co., Ltd, a China-based biotech firm, has announced that it has received...

Company Drug

Boehringer Ingelheim and Eli Lilly’s Jardiance Receives NMPA Approval for CKD Treatment

Fineline Cube Nov 24, 2023

Boehringer Ingelheim (BI) and Eli Lilly (NYSE: LLY) have announced that their SGLT2 inhibitor, Jardiance...

Company Deals

Zhejiang Huanqing Medical Technology Secures Series A Financing for Heart Failure Innovations

Fineline Cube Nov 24, 2023

Zhejiang Huanqing Medical Technology Co., Ltd, a Chinese specialist in heart failure solutions, has reportedly...

Company Drug

Boehringer Ingelheim and Eli Lilly Secure NMPA Approval for Jardiance in Chronic Kidney Disease

Fineline Cube Nov 24, 2023

Boehringer Ingelheim (BI) and Eli Lilly (NYSE: LLY) have announced the receipt of marketing approval...

Posts pagination

1 … 379 380 381 … 606

Recent updates

  • Johnson & Johnson Strikes Tariff Exemption Deal with Trump Administration
  • Hybio Pharmaceutical Licenses Semaglutide to Vitamedic for Brazil Market
  • Merck in Talks to Acquire Revolution Medicines for $28‑32 Billion in Oncology Push
  • Genrix Bio’s GR1803 NDA Accepted for BCMA-Targeted Multiple Myeloma Therapy
  • RemeGen’s RC48 Wins Fourth Breakthrough Therapy Designation for Gastric Cancer Combo
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Others

Johnson & Johnson Strikes Tariff Exemption Deal with Trump Administration

Company Deals

Hybio Pharmaceutical Licenses Semaglutide to Vitamedic for Brazil Market

Company Deals

Merck in Talks to Acquire Revolution Medicines for $28‑32 Billion in Oncology Push

Company Drug

Genrix Bio’s GR1803 NDA Accepted for BCMA-Targeted Multiple Myeloma Therapy

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.